CAR-T cells treat solid tumors effectively, study shows

Researchers have demonstrated, for the first time, the effectiveness of CAR-T cell therapy against solid tumors, marking a significant breakthrough in cancer treatment. A study involving patients with advanced stomach or esophageal cancer showed those treated with CAR-T cells lived an average of 2.4 months longer and had a 31% lower risk of death compared to those receiving standard treatment. The therapy reprograms the patient's immune cells to fight cancer. CAR-T cell therapy, currently approved in Sweden for certain blood cancers, has previously been ineffective against solid tumors. This study suggests potential for future treatment of solid tumor cancers, despite significant side effects.